CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 168 enrolled
Drug / intervention
JUVÉDERM® VOLUMA® with Lidocainedevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04891419
NCT04891419Phase 3Completed
CompareCT.gov

A Multicenter, Evaluator-blinded, Randomized, No-treatment Controlled Study to Evaluate the Safety and Effectiveness of JUVÉDERM® VOLUMA® With Lidocaine for Correction of Temple Hollowing in Chinese Population

Allergan·interventional·Posted May 18, 2021·Updated Dec 12, 2024

In Brief

A Phase 3 clinical trial evaluating JUVÉDERM® VOLUMA® with Lidocaine for Temple Hollowing. Completed, enrolled 168 participants across 8 sites.

Detailed Summary

The objectives of this study are to evaluate the safety and effectiveness of JUVÉDERM® VOLUMA® with Lidocaine injectable gel in adult Chinese population seeking correction of temple hollowing.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTemple Hollowing
CountriesChina
Collaborators--

Timeline

Phase 3CompletedFinished
20222023202420252026
First PostedMay 18, 2021
Enrollment StartJul 20, 2021
Primary CompletionNov 22, 2023
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 5.1 years ago

Interventions

JUVÉDERM® VOLUMA® with Lidocainedevice

JUVÉDERM® VOLUMA® with Lidocaine injectable gel